OGT 2378

Drug Profile

OGT 2378

Latest Information Update: 22 Jun 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator UCB
  • Class Antineoplastics; Imino sugars; Piperidines
  • Mechanism of Action Glucosylceramide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Malignant melanoma

Most Recent Events

  • 08 Dec 2003 The integration of Oxford GlycoSciences into Celltech Group has been completed
  • 15 Sep 2003 A preclinical study has been added to the adverse events, pharmacokinetics and Cancer pharmacodynamics sections
  • 12 Aug 2003 Oxford GlycoSciences has been acquired by Celltech Group
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top